Background. Treatment resistance to biologic treatment at specific sites in the body is a
challenging issue. However, there is insufficient evidence for factors affecting the resistance …

Introduction: Data that can identify the patients who will not respond to anti-TNF agents are
sparse. Therefore, the authors wished to describe specific clinical factors that could be …

Background: Anti-tumor necrosis factor (TNF)-α therapies represent a significant innovation
in therapy for psoriasis. However, a significant number of psoriasis patients do not respond …

Although the heterogeneity of the therapeutic response to TNF‐α blockers seems to be
mainly due to genetic factors, several studies showed that a range of factors may influence it …

The biologic agents are effective drugs to treat psoriasis. They provide physicians with
additional options for patients who cannot tolerate traditional therapies or for whom …

Objective The aim of this paper is to discuss usefulness of examining TNF- expression
changes and its TNFR1 and TNFR2 as markers for early detection of loss of therapeutic …

Background There is limited information on patients undergoing withdrawal after long-term
treatment with anti-TNF alpha drugs and their clinical evolution during the post-interruption …

Psoriasis is a chronic, immune‐mediated inflammatory disease for which no definitive cure
exists and patients difficult to treat with moderate to severe psoriasis often require life‐long …

■ Abstract In contrast to many other diseases, modern psoriasis therapy has a fairly brief
history. Until about 15 years ago, clinicians and their patients had few options, with limited …

Discussion Patients with mild disease may obtain symptomatic relief with topical agents and
targeted phototherapy. Patients with moderate-to-severe disease are likely to benefit from …